Clinical Trial Update: Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age [Phase 3]

View source ↗

Summary

A Phase 3 study comparing safety and immunogenicity of the Tdap vaccine to the DTaP vaccine in children aged 4 to 6 years, with results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pertussis
• Tetanus

Drugs mentioned

• ADACEL (Tdap vaccine (tetanus, diphtheria and acellular pertussis vaccine))
• DAPTACEL (Diphtheria Tetanus Acellular Pertussis Vaccine Adsorbed)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Tetanus, Diphtheria | Phase 3 | Status: COMPLETED | Results posted: 2010-12-03